Clinical Trials Logo

Filter by:
NCT ID: NCT05156528 Recruiting - Shigellosis Clinical Trials

Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years

Start date: December 11, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in infants and children aged from 6 months to 5 years.

NCT ID: NCT05156515 Recruiting - Lung Cancer Clinical Trials

PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor

Start date: December 9, 2021
Phase: N/A
Study type: Interventional

The objective of this study is to construct a noninvasive approach using 68Ga-THP-APN09 PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.

NCT ID: NCT05156281 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

REMODEL-2
Start date: December 13, 2021
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

NCT ID: NCT05155969 Recruiting - Clinical trials for Postoperative Depression

Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Esketamine is a general anesthetic with anti-depressant effects at subanaesthetic doses. This study hypothesized that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients.

NCT ID: NCT05155839 Recruiting - Clinical trials for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Start date: June 25, 2019
Phase: Phase 1
Study type: Interventional

This study consists of two parts. Phase Ia is a dose escalation study to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of MRG001. Phase Ib is a dose expansion study to assess the preliminary efficacy of MRG001 in patients with CD20-positive relapsed or refractory B-cell NHL at the confirmed RP2D. The safety, tolerability, pharmacokinetic (PK) and immunogenicity of MRG001 will be evaluated in both parts.

NCT ID: NCT05155722 Recruiting - Clinical trials for Advanced Solid Tumor

Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors

Start date: September 17, 2020
Phase: Phase 1
Study type: Interventional

A phase I dose escalation and cohort expansion study to evaluate the safety, tolerance and pharmacokinetic of BAT1308 injection in patients with advanced solid tumors

NCT ID: NCT05155657 Recruiting - Alcoholic Cirrhosis Clinical Trials

Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells

Start date: June 13, 2022
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety and tolerance of umbilical cord mesenchymal stem cells (UCMSCs) in patients with decompensated alcoholic cirrhosis, and to provide dose basis for subsequent clinical study design. We will also explore the possible mechanism of UCMSCs in the treatment of decompensated alcoholic cirrhosis (DAC).

NCT ID: NCT05155592 Recruiting - Uveitis Clinical Trials

Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

TNF-α inhibitors, like Adalimumab, have good efficacy in non-infectious uveitis, but long-term use can increase the risk of drugs, and the patient's financial burden is large. The objective of this study was to explore the reduction or withdrawal of Adalimumab in uveitis patients with stable drug control, and to evaluate the efficacy and safety of drug reduction in uveitis patients, as well as the impact on their vision prognosis.

NCT ID: NCT05155449 Recruiting - Gut Function Clinical Trials

Probiotic Intervention for Gut Function

Start date: February 8, 2023
Phase: N/A
Study type: Interventional

The effect of probiotics on gut function in healthy subjects.

NCT ID: NCT05155358 Recruiting - Kidney Injury Clinical Trials

Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Heat Stroke

Start date: November 1, 2021
Phase:
Study type: Observational

Heat stroke is a clinical syndrome with high incidence and high fatality rate in summer. Patients with liver, kidney, and brain damage are prone to secondary MODS, and the prognosis is poor due to high medical costs. At present, there is no unified diagnostic criteria for acute liver injury associated with heat stroke, and the commonly used prognosis scores are rarely included in liver injury indicators, which is not good for practicality.